232 related articles for article (PubMed ID: 24583671)
21. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.
Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V
J Int AIDS Soc; 2017 Apr; 20(1):21362. PubMed ID: 28453240
[TBL] [Abstract][Full Text] [Related]
22. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.
Adjé-Touré C; Celestin B; Hanson D; Roels TH; Hertogs K; Larder B; Diomande F; Peeters M; Eholié S; Lackritz E; Chorba T; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S23-9. PubMed ID: 14565606
[TBL] [Abstract][Full Text] [Related]
24. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
[TBL] [Abstract][Full Text] [Related]
25. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
Seyler C; Adjé-Touré C; Messou E; Dakoury-Dogbo N; Rouet F; Gabillard D; Nolan M; Toure S; Anglaret X
AIDS; 2007 May; 21(9):1157-64. PubMed ID: 17502726
[TBL] [Abstract][Full Text] [Related]
26. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
[TBL] [Abstract][Full Text] [Related]
27. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines.
Kebe K; Thiam M; Diagne Gueye NR; Diop H; Dia A; Signate Sy H; Charpentier C; Belec L; Mboup S; Toure Kane C
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):242-9. PubMed ID: 22860571
[TBL] [Abstract][Full Text] [Related]
28. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).
Breilh D; Pellegrin I; Rouzés A; Berthoin K; Xuereb F; Budzinski H; Munck M; Fleury HJ; Saux MC; Pellegrin JL
AIDS; 2004 Jun; 18(9):1305-10. PubMed ID: 15362663
[TBL] [Abstract][Full Text] [Related]
29. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.
Landman R; de Truchis P; Assoumou L; Lambert S; Bellet J; Amat K; Lefebvre B; Allavena C; Katlama C; Yazdanpanah Y; Molina JM; Petrov-Sanchez V; Gibowski S; Alvarez JC; Leibowitch J; Capeau J; Fellahi S; Duracinsky M; Morand-Joubert L; Costagliola D; Alvarez JC; Girard PM;
Lancet HIV; 2022 Feb; 9(2):e79-e90. PubMed ID: 35120640
[TBL] [Abstract][Full Text] [Related]
30. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.
Johannessen A; Naman E; Kivuyo SL; Kasubi MJ; Holberg-Petersen M; Matee MI; Gundersen SG; Bruun JN
BMC Infect Dis; 2009 Jul; 9():108. PubMed ID: 19583845
[TBL] [Abstract][Full Text] [Related]
31. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
[TBL] [Abstract][Full Text] [Related]
32. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.
Delaugerre C; Braun J; Charreau I; Delarue S; Nere ML; de Castro N; May T; Marchou B; Simon F; Molina JM; Aboulker JP;
HIV Med; 2012 Oct; 13(9):517-25. PubMed ID: 22416781
[TBL] [Abstract][Full Text] [Related]
33. Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.
Messou E; Chaix ML; Gabillard D; Yapo V; Toni TD; Minga A; Kouakou MG; Ouattara E; Rouzioux C; Danel C; Eholie SP; Anglaret X
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):211-9. PubMed ID: 23797690
[TBL] [Abstract][Full Text] [Related]
34. Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
Adawaye C; Fokam J; Kamangu E; Alio HM; Chahad AM; Susin F; Moussa AM; Bertin TH; Tidjani A; Vaira D; Moutschen M
BMC Res Notes; 2017 Nov; 10(1):589. PubMed ID: 29126456
[TBL] [Abstract][Full Text] [Related]
35. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
36. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.
Ruelle J; Roman F; Vandenbroucke AT; Lambert C; Fransen K; Echahidi F; Piérard D; Verhofstede C; Van Laethem K; Delforge ML; Vaira D; Schmit JC; Goubau P
BMC Infect Dis; 2008 Feb; 8():21. PubMed ID: 18304321
[TBL] [Abstract][Full Text] [Related]
37. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Péré H; Charpentier C; Mbelesso P; Dandy M; Matta M; Moussa S; De Dieu Longo J; Grésenguet G; Abraham B; Bélec L
AIDS Res Hum Retroviruses; 2012 Apr; 28(4):315-23. PubMed ID: 21942692
[TBL] [Abstract][Full Text] [Related]
38. High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.
de Truchis P; Lê MP; Daou M; Madougou B; Nouhou Y; Moussa Saley S; Sani A; Adehossi E; Rouveix E; Saidou M; Peytavin G; Delaugerre C
J Antimicrob Chemother; 2016 Nov; 71(11):3222-3227. PubMed ID: 27439522
[TBL] [Abstract][Full Text] [Related]
39. Virological Suppression and Patterns of Resistance Amongst Patients on Antiretroviral Therapy at 4 Nigerian Military Hospitals.
Babajide K; Ayemoba O; Terfa K; Ake J; Crowell TA; Adamu Y; Mohammed T; Okoye I; Odeyemi S; Crawford K; Hughes L; Akintunde E; Umar T; Hamm TE; Njoku OS
Curr HIV Res; 2017; 15(2):146-151. PubMed ID: 28521719
[TBL] [Abstract][Full Text] [Related]
40. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Lambert-Niclot S; Grude M; Chaix ML; Charpentier C; Reigadas S; Le Guillou-Guillemette H; Rodallec A; Amiel C; Maillard A; Dufayard J; Mourez T; Mirand A; Guinard J; Montes B; Vallet S; Marcelin AG; Descamps D; Flandre P; Delaugerre C; Morand-Joubert L;
J Antimicrob Chemother; 2018 Aug; 73(8):2147-2151. PubMed ID: 29718247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
